Type of non Hodgkin's lymphoma-Diffuse large B-cell lymphoma - Page 2 of 7 Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor

Evaluating the impact of surgical removal of tumors in non-Hodgkin lymphoma.

Evaluating the impact of surgical removal of tumors in non-Hodgkin lymphoma.

Posted by on Sep 29, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effectiveness of complete surgical removal of aggressive non-Hodgkin lymphoma (NHL). The authors found that in young patients with diffuse large B-cell lymphoma (DLBCL) may benefit from complete surgical removal of the tumor before immunochemotherapy (ICT).  Some background Lymphoma is a cancer that...

Read More

Outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas

Outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas

Posted by on Sep 13, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the effectiveness and safety of lisocabtagene maraleucel (Liso-cel) in treating patients with relapsed or refractory (r/r) large B-cell lymphomas (LBCL). The authors found that liso-cel achieved fast and lasting remission with fewer toxicities in such patients. Some background Patients with r/r-LBCL experience...

Read More

How does COVID-19 affect patients with cancer undergoing chemotherapy?

How does COVID-19 affect patients with cancer undergoing chemotherapy?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...

Read More

How effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?

How effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if adding biological therapy rituximab (Rituxan) to chemotherapy improved treatment results for children with non-Hodgkin lymphoma. The results showed that rituximab improved patients’ chances of survival but also caused more side effects. Some background Treatment results for children with NHL have...

Read More

Which patients with diffuse large B cell lymphoma benefit most from CAR-T treatment?

Which patients with diffuse large B cell lymphoma benefit most from CAR-T treatment?

Posted by on Jun 7, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of CAR-T treatment for patients with diffuse large B cell lymphoma (DLBCL). The authors found that while a significant number of all patients benefitted from the treatment, some patients were more likely to benefit from it than others. Some background During initial treatment for DLBCL,...

Read More

Which chemotherapy combination causes less kidney damage to patients with non-Hodgkin lymphoma?

Posted by on May 9, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared two chemotherapy combinations – R-DHAP and R-DHAOx – to see which caused less kidney damage in patients with non-Hodgkin lymphoma (NHL). The results showed that fewer patients receiving R-DHAOx developed poor kidney function than patients receiving R-DHAP. Some background Combinations of chemotherapy...

Read More

How common are side effects of the heart in patients with non-Hodgkin lymphoma who receive CHOP or R-CHOP chemotherapy?

Posted by on Apr 25, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how common side effects of the heart, including heart failure, were among patients with non-Hodgkin lymphoma who received CHOP or R-CHOP chemotherapy. The results showed that only a minority developed side effects and that older patients and female patients were more likely to develop them. Some background Both...

Read More

Evaluating pembrolizumab plus R-CHOP chemotherapy for patients with untreated diffuse large B-cell lymphoma

Posted by on Mar 10, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that pembrolizumab can be safely added to R-CHOP, with improved survival outcomes. Some...

Read More

Evaluating mental performance in older survivors of non-Hodgkin lymphoma

Posted by on Feb 22, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated mental functioning in older survivors of non-Hodgkin lymphoma (NHL). This study concluded that these individuals may have some mental function decline and lower mental function compared to individuals who did not have cancer. Some background Research suggests that cancer treatments have been shown to cause...

Read More